Brokerage Reports
IDEAYA Biosciences, Inc. [IDYA]
Reports for Purchase
Showing records 141 - 160 ( 172 total )
Company: IDEAYA Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
IDEAYA Clinical Collaboration With Pfizer Expanded to Include Combination of IDE196 With Xalkori
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Price: 10.00
Company: IDEAYA Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
Price: 25.00
Company: IDEAYA Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
Upcoming Webinars to Discuss Near-Term Catalysts with Our Covered Companies
Provider: Roth Capital Partners, Inc.
Analyst: JALLAH Z
Price: 10.00
Company: IDEAYA Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
2Q20 Results; First Synthetic Lethality Candidate Could Reach the Clinic in 1H21
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Price: 25.00
Company: IDEAYA Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
Price: 10.00
Company: IDEAYA Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
2Q20 Earnings - $300M in Cash Should Accelerate Clinical Development
Provider: Roth Capital Partners, Inc.
Analyst: JALLAH Z
Price: 25.00
Company: IDEAYA Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
Price: 10.00
Company: IDEAYA Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
GSK''s Highlighting of Ideaya''s Synthetic Lethality Pipeline Speaks Loads
Provider: Roth Capital Partners, Inc.
Analyst: JALLAH Z
Price: 25.00
Company: IDEAYA Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
Price: 10.00
Company: IDEAYA Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
Criteria Met for Expansion in Phase 2 Basket Trial in Skin Melanoma
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Price: 10.00
Company: IDEAYA Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
Update Highlights Broader Market Opportunity for IDE196. Readout in 1H21.
Provider: Roth Capital Partners, Inc.
Analyst: JALLAH Z
Price: 25.00
Company: IDEAYA Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
Price: 10.00
Company: IDEAYA Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
First Patient Dosed in Combination Trial of IDE196 and Mektovi for Metastatic Uveal Melanoma
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Price: 10.00
Company: IDEAYA Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
First Patient Dosed in Phase 1 Combo Trial of IDE196 + Binimetinib
Provider: Roth Capital Partners, Inc.
Analyst: JALLAH Z
Price: 10.00
Company: IDEAYA Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
Price: 10.00
Company: IDEAYA Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
AACR Updates Provide Detailed Insights Into Ideaya''s Pipeline Potential
Provider: Roth Capital Partners, Inc.
Analyst: JALLAH Z
Price: 25.00
Company: IDEAYA Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
Price: 10.00
Company: IDEAYA Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
Potential $3 Billion Partnership With GSK for Preclinical Synthetic Lethality Programs; Raising PT to $22
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Price: 25.00
Company: IDEAYA Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
Synthetic Lethality Pipeline Enters the Spotlight - Increasing PT to $23
Provider: Roth Capital Partners, Inc.
Analyst: JALLAH Z
Price: 25.00
Company: IDEAYA Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
Price: 10.00